Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
How did ASX biotech shares perform in FY22?
Why the IDT Australia (ASX:IDT) share price is crashing 37% lower today
Why is the IDT (ASX:IDT) share price halted today?
IDT (ASX:IDT) share price swings as CEO lauds mRNA tech in fight against Omicron
Share Market News
The Starpharma (ASX: SPL) share price surges on Vietnam launch
IDT Australia (ASX:IDT) share price rockets 40% on COVID vaccine update
Here’s why the IDT Australia (ASX:IDT) share price is up 75% in a month.
IDT Australia (ASX: IDT) share price surges 16% on vaccine government talks
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services.
|16 Aug 2022||$0.14||$0.00||0.00%||196,924||$0.15||$0.15||$0.14|
|15 Aug 2022||$0.15||$0.00||0.00%||318,277||$0.15||$0.15||$0.14|
|12 Aug 2022||$0.15||$-0.01||-6.67%||117,004||$0.14||$0.15||$0.14|
|11 Aug 2022||$0.15||$0.01||6.90%||66,177||$0.15||$0.15||$0.14|
|10 Aug 2022||$0.15||$-0.01||-6.67%||2,077,354||$0.15||$0.15||$0.15|
|08 Aug 2022||$0.15||$0.00||0.00%||142,122||$0.15||$0.15||$0.14|
|04 Aug 2022||$0.15||$0.02||14.81%||74,799||$0.14||$0.15||$0.14|
|03 Aug 2022||$0.14||$-0.01||-6.90%||177,128||$0.13||$0.15||$0.13|
|02 Aug 2022||$0.15||$-0.01||-6.67%||222,557||$0.15||$0.15||$0.15|
|01 Aug 2022||$0.15||$0.00||0.00%||1,641,189||$0.14||$0.15||$0.13|
|29 Jul 2022||$0.15||$0.01||7.14%||72,029||$0.14||$0.15||$0.14|
|27 Jul 2022||$0.14||$-0.02||-12.90%||405,358||$0.15||$0.15||$0.14|
|26 Jul 2022||$0.16||$0.01||6.67%||41,577||$0.15||$0.16||$0.14|
|25 Jul 2022||$0.15||$-0.02||-12.12%||75,343||$0.15||$0.16||$0.14|
|22 Jul 2022||$0.17||$0.00||0.00%||52,050||$0.15||$0.17||$0.15|
|21 Jul 2022||$0.17||$0.01||6.25%||40,876||$0.16||$0.17||$0.16|
|20 Jul 2022||$0.16||$-0.01||-6.06%||109,007||$0.16||$0.16||$0.15|
|26 Aug 2021||Maria (Mary) Sontrop||Sell||275||$175,065|| |
|Mr Alan David Fisher||Non-Executive DirectorNon-Executive Chairman||Jun 2015|| |
Mr Fisher is experienced corporate advisor and public company director. His main areas of experience include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice. Currently, he is Non-Executive Chair of Centrepoint Alliance Ltd, Non-Executive Director and Chair of Audit and Risk Committees of Bionomics Ltd and Thorney Technologies Ltd, and Non Executive Director of Simavita Ltd. He is a member of the Risk committee.
|Mr Michael John Kotsanis||Non-Executive Director||Mar 2020|| |
Mr Kotsanis over 30 years of strategic and operational experience in the global pharmaceutical industry. Michael was appointed as CEO of Acrux Ltd in November 2014. He was formerly the Chief Commercial Officer and a Board Member of Synthon Holding BV, a Dutch based international pharmaceutical company with revenue over EUR250 million, a position he held for four years. Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira. Michael joined Hospira following its acquisition of Mayne Pharma in 2007, where he had served as President, Asia Pacific from 2002. He joined Mayne following their acquisition of FH Faulding in 2001, where he held responsibility for commercial activities of the pharmaceutical business in Australia and New Zealand. Michael was formerly a Board Member of the European Generics Association and a Director of the Generic Medicines Industry of Australia. He is a member of the Risk committee.
|Mr Hugh Nigel Burrill||Non-Executive Director||Oct 2015|| |
Mr Burrill was Corporate Vice President, Global Pharma Research & Development, Hospira Inc where he was responsible for overall pipeline portfolio management, and research and development of generic and specialty pharmaceuticals. Prior to this he held senior international roles within Hospira Inc and the original Mayne Pharma Ltd and currently provides consulting services in pharmaceutical strategic management, product development, regulatory affairs and intellectual property. He is Chair of the Risk committee.
|Dr Jane Ryan||Non-Executive Director||Jan 2022|| |
Dr Ryan has commercial pharmaceuticals background with over 30 years of international experience in the pharmaceutical and biotechnology industries having worked in Australia, US and UK. She has held senior executive roles in management of research and development programs as well as business development and alliance management. Throughout her career, she has led many fundraising campaigns and licensing initiatives including the US Government contract. Jane is currently a Non-Executive Director of Anatara Lifesciences Ltd and Bionomics Ltd.
|Dr David Sparling||Joint Company SecretaryChief Executive Officer||Feb 2018|| |
|Ms Ancila Desai||Chief Financial OfficerJoint Company Secretary||Jun 2020|| |
|Ancila Desai||Chief Financial OfficerJoint Company Secretary|| |
|Paul McDonald||Head of Quality and Development|| |
|David Sparling||Joint Company SecretaryChief Executive Officer|| |
|Jim Sosic||Vice President Operations Supply and Infrastructure|| |
|UBS Nominees Pty Ltd||20,402,924||8.51%|
|HSBC Custody Nominees (Australia) Limited||19,773,269||8.24%|
|One Managed Invt Funds Ltd||18,161,934||7.57%|
|Citicorp Nominees Pty Limited||15,811,239||6.59%|
|One Fund Services Ltd||8,398,434||3.50%|
|Brispot Nominees Pty Ltd||8,004,797||3.34%|
|Mr Anthony John Huntley||7,500,000||3.13%|
|Graeme Leslie Blackman||7,029,710||2.93%|
|CS Third Nominees Pty Limited||6,141,162||2.56%|
|CS Fourth Nominees Pty Limited||5,838,039||2.43%|
|Jamplat Pty Ltd||5,725,000||2.39%|
|J P Morgan Nominees Australia Pty Limited||4,786,001||2.00%|
|I'Rom Group Co Ltd||3,766,035||1.57%|
|Mr Rodney Bruce Ebsworth||3,750,000||1.56%|
|Picherit'S Farm Pty Ltd||3,500,000||1.46%|
|Goen Investments Pty Ltd||2,500,000||1.04%|
|Mr Anthony John Huntley (i)||2,500,000||1.04%|
|Mr Gavin George Rogers & Ms Kathryn Ann Rogers||2,500,000||1.04%|